Working to Eradicate Gynecologic Cancers

241 - Poster Session A
Solitomab, an EpCAM/CD3 bispecific antibody (BiTE®), is highly active against primary chemotherapy-resistant ovarian cancer cell lines in vitro and fresh tumor cells ex vivo

Saturday, March 22, 2014: 7:25 PM
West Exhibit Hall (Tampa Convention Center)
D. P. English, C. L. Schwab, D. M. Roque, S. Bellone, E. S. Ratner, D. A. Silasi, M. Azodi, P. E. Schwartz, T. J. Rutherford and A. Santin
Yale University School of Medicine, New Haven, CT
 
See more of: Poster Session A
See more of: Poster Session
<< Previous Presentation | Next Presentation >>